CA2274756C - Methods and pharmaceutical compositions for inhibiting tumour cell growth - Google Patents

Methods and pharmaceutical compositions for inhibiting tumour cell growth Download PDF

Info

Publication number
CA2274756C
CA2274756C CA002274756A CA2274756A CA2274756C CA 2274756 C CA2274756 C CA 2274756C CA 002274756 A CA002274756 A CA 002274756A CA 2274756 A CA2274756 A CA 2274756A CA 2274756 C CA2274756 C CA 2274756C
Authority
CA
Canada
Prior art keywords
benzyl
dione
ppary
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002274756A
Other languages
English (en)
French (fr)
Other versions
CA2274756A1 (en
Inventor
Bruce M. Spiegelman
Soner Altiok
Elisabetta Mueller
Pasha Sarraf
Peter Tontonoz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/923,346 external-priority patent/US6552055B2/en
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA2274756A1 publication Critical patent/CA2274756A1/en
Application granted granted Critical
Publication of CA2274756C publication Critical patent/CA2274756C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002274756A 1996-12-11 1997-12-11 Methods and pharmaceutical compositions for inhibiting tumour cell growth Expired - Fee Related CA2274756C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US76655396A 1996-12-11 1996-12-11
US08/766,553 1996-12-11
US08/923,346 US6552055B2 (en) 1996-12-11 1997-09-04 Methods and pharmaceutical compositions for inhibiting tumor cell growth
US08/923,346 1997-09-04
PCT/US1997/022879 WO1998025598A2 (en) 1996-12-11 1997-12-11 Methods and pharmaceutical compositions for inhibiting tumour cell growth

Publications (2)

Publication Number Publication Date
CA2274756A1 CA2274756A1 (en) 1998-06-18
CA2274756C true CA2274756C (en) 2007-03-13

Family

ID=27117766

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002274756A Expired - Fee Related CA2274756C (en) 1996-12-11 1997-12-11 Methods and pharmaceutical compositions for inhibiting tumour cell growth

Country Status (8)

Country Link
US (1) US7635708B2 (https=)
EP (2) EP1410799B1 (https=)
JP (2) JP4549443B2 (https=)
AT (2) ATE253903T1 (https=)
AU (1) AU5601898A (https=)
CA (1) CA2274756C (https=)
DE (2) DE69739828D1 (https=)
WO (1) WO1998025598A2 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586455B1 (en) * 1996-12-31 2003-07-01 The Salk Institute For Biological Studies Treatment of liposarcomas using a combination of thiazolidinediones and retinoid X receptor selective agonists
US5814647A (en) 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
FR2773075B1 (fr) * 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
AU1707599A (en) * 1998-03-20 1999-10-18 Warner-Lambert Company Retinoid-glitazone combinations
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO2000030628A2 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Method of inhibiting angiogenesis
GB9908647D0 (en) * 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
GB9917405D0 (en) * 1999-07-23 1999-09-22 Univ Dundee Methods of treatment and drug screening methods
US6723506B2 (en) 2000-01-20 2004-04-20 Brigham And Women's Hospital Method of identifying PAX8-PPAR gamma-nucleic acid molecules
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
AU2001278738A1 (en) * 2000-08-16 2002-02-25 Sankyo Company Limited Medicinal compositions for preventing and treating cancer
AU8856201A (en) 2000-09-01 2002-03-13 Andel Inst Van Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
US7323481B2 (en) 2001-04-06 2008-01-29 Hoffmann-La Roche Inc. Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth
US6756399B2 (en) 2001-06-29 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
US20040197834A1 (en) * 2001-07-20 2004-10-07 Francois Gervais Method to increase expression of pgd2 receptors and assays for identifying modulators of prostaglandin d2 receptors
WO2003032988A1 (fr) * 2001-10-17 2003-04-24 Sankyo Company, Limited Composition pharmaceutique
AU2002354460A1 (en) * 2001-12-11 2003-07-09 Sankyo Company, Limited Medicinal composition
JP5249484B2 (ja) * 2001-12-11 2013-07-31 第一三共株式会社 医薬組成物
WO2003082865A1 (en) * 2002-04-01 2003-10-09 Sankyo Company, Limited Medicinal antitumor composition
JP2004083574A (ja) * 2002-06-25 2004-03-18 Sankyo Co Ltd 利尿剤及びペルオキシソーム増殖因子活性化受容体（ＰＰＡＲ）γ活性化剤を含有する医薬組成物
WO2004000356A1 (ja) * 2002-06-25 2003-12-31 Sankyo Company, Limited 利尿剤及びペルオキシソーム増殖因子活性化受容体（PPAR)γ活性化剤を含有する医薬組成物
HU0301358D0 (en) 2003-05-14 2003-07-28 Debreceni Egyetem Novel use of ppargamma agonists
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
NZ544472A (en) 2003-07-03 2009-04-30 Myriad Genetics Inc Compounds and therapeutical use thereof
TWI297606B (en) * 2004-01-16 2008-06-11 Nat Health Research Institutes Cancer therapy
JP4556511B2 (ja) * 2004-06-25 2010-10-06 ソニー株式会社 １５ｄ−ＰＧＪ２、及び、１５ｄ−ＰＧＪ２を用いた方法
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
JP2006232754A (ja) * 2005-02-25 2006-09-07 Gi Biopolis:Kk 消化管粘膜切除後の消化管潰瘍治癒促進用スプレー剤
WO2006099479A2 (en) * 2005-03-14 2006-09-21 Immunomedics, Inc. Methods of treating cancer using ppar-gamma antagonists
JP2008538351A (ja) 2005-03-21 2008-10-23 メタボレックス インコーポレーティッド 癌を含むＰＰＡＲγ反応性疾患の処置または予防における浮腫を回避するための方法
BRPI0616454A2 (pt) 2005-09-30 2011-06-21 Vitae Pharmaceuticals, Inc. métodos de tratamento de cáncer
EP1964575B1 (en) 2005-11-28 2015-09-23 Senju Pharmaceutical Co., Ltd. Pharmaceutical comprising ppar agonist
US8802705B2 (en) 2007-05-21 2014-08-12 Senju Pharmaceutical Co., Ltd. Pharmaceutical containing PPAR delta agonist
WO2010070379A1 (en) * 2008-12-17 2010-06-24 Centre National De La Recherche Scientifique Rxr-ppargamma agonist/growth factor inhibitor combination therapy for inducing apoptosis and the treatment of cancer
AU2012275190B2 (en) 2011-06-29 2016-05-19 The Penn State Research Foundation Compositions, methods and kits for treating leukemia
MX352727B (es) 2011-12-13 2017-12-06 Dartmouth College Tratamiento de trastorno autoinmune al usar agonistas de rxr.
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
JP5987175B2 (ja) * 2012-07-02 2016-09-07 学校法人福岡大学 乳癌，胃癌及び卵巣癌等に対する制癌剤
ES2668310T3 (es) 2012-11-05 2018-05-17 Commissariat à l'énergie atomique et aux énergies alternatives Combinación de un agente anticanceroso tal como un inhibidor de la tirosina cinasa y un antagonista STAT5, preferiblemente una tiazolidindiona, para eliminar las células madre de cáncer hematológico in vivo y para prevenir la recidiva de cáncer hematológico
CN107073079A (zh) * 2014-09-08 2017-08-18 达纳－法伯癌症研究所公司 包括给予PPAR‑γ激动剂的治疗癌症的方法
WO2017075607A1 (en) 2015-10-31 2017-05-04 Io Therapeutics, Inc. Treatment of nervous system disorders using combinations of pxr agonists and thyroid hormones
WO2017075612A1 (en) * 2015-10-31 2017-05-04 Io Therapeutics, Inc. Treatment of cancer with combinations of rxr agonists and thyroid hormones
US10960013B2 (en) * 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
KR20180121983A (ko) 2016-03-10 2018-11-09 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 근육 질환의 치료
CA3016876C (en) 2016-03-10 2021-12-28 Io Therapeutics, Inc. Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
US11517549B2 (en) 2017-09-20 2022-12-06 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
CA3191858A1 (en) * 2020-09-08 2022-03-17 National University Corporation Ehime University Fluorescent dye and method for detecting tumor cells
CA3242047A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist in treating drug resistant her2+ cancers
MX2024006978A (es) 2021-12-07 2024-07-19 Io Therapeutics Inc Uso de un agonista de rxr y taxanos en el tratamiento de cáncer her2+.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
DE10199033I2 (de) * 1992-04-22 2003-01-09 Ligand Parmaceuticals Inc Retinoid-x Rezeptor selektive Verbindungen
US5552271A (en) 1992-06-16 1996-09-03 La Jolla Cancer Research Foundation RXR homodimer formation
US5466861A (en) 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
US5521202A (en) 1993-04-07 1996-05-28 Taiho Pharmaceutical Co., Ltd. Thiazolidine derivatives and pharmaceutical compositions containing the same
EP0724636A1 (en) 1993-10-22 1996-08-07 Ligand Pharmaceuticals, Inc. Human peroxisome proliferator activated receptor
WO1995018533A1 (en) 1994-01-04 1995-07-13 The Trustees Of The University Of Pennsylvania Methods and compounds affecting adipocyte differentiation and obesity
US5514821A (en) 1994-05-27 1996-05-07 Ligand Pharmaceuticals Incorporated Ring-labeled retinoids and intermediates, and methods for their synthesis and use
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
CA2194169A1 (en) 1994-07-01 1996-01-18 Ronald M. Evans Mammalian peroxisome proliferator-activated receptors and uses thereof
CA2193685A1 (en) 1994-07-01 1996-01-18 Ranjan Mukherjee Screening for nuc inhibitors
ES2133798T3 (es) 1994-08-10 1999-09-16 Hoffmann La Roche Ligandos del receptor x del acido retinoico.
US6022897A (en) * 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
EP0824583A1 (en) * 1995-05-04 1998-02-25 City Of Hope Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
ATE259227T1 (de) * 1995-09-18 2004-02-15 Ligand Pharm Inc Behandlung von niddm (nichtinsulinabhängige diabetes mellitus) mit rxr agonisten
WO1997017091A1 (en) * 1995-11-08 1997-05-15 University Of South Florida Guinea pig model for leiomyomas and atherosclerosis
US5814647A (en) 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms

Also Published As

Publication number Publication date
JP4549443B2 (ja) 2010-09-22
WO1998025598A2 (en) 1998-06-18
JP4550133B2 (ja) 2010-09-22
ATE462433T1 (de) 2010-04-15
EP0948324A2 (en) 1999-10-13
EP1410799B1 (en) 2010-03-31
DE69726182D1 (de) 2003-12-18
EP1410799A1 (en) 2004-04-21
US20030144330A1 (en) 2003-07-31
WO1998025598A3 (en) 1998-07-30
EP0948324B1 (en) 2003-11-12
AU5601898A (en) 1998-07-03
DE69726182T2 (de) 2004-08-12
DE69739828D1 (de) 2010-05-12
ATE253903T1 (de) 2003-11-15
JP2001510462A (ja) 2001-07-31
JP2009063566A (ja) 2009-03-26
US7635708B2 (en) 2009-12-22
CA2274756A1 (en) 1998-06-18

Similar Documents

Publication Publication Date Title
CA2274756C (en) Methods and pharmaceutical compositions for inhibiting tumour cell growth
US6242196B1 (en) Methods and pharmaceutical compositions for inhibiting tumor cell growth
US6552055B2 (en) Methods and pharmaceutical compositions for inhibiting tumor cell growth
WO1998025598A9 (en) Methods and pharmaceutical compositions for inhibiting tumour cell growth
US5814647A (en) Use of troglitazone and related compounds for the treatment of the climacteric symptoms
Kubota et al. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
US6756399B2 (en) Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
Klopper et al. Retinoid X receptor-γ and peroxisome proliferator-activated receptor-γ expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment
US20140187495A1 (en) Methods for treating glioblastoma
US6673823B2 (en) Use of peroxisome proliferator activated receptor (PPAR)-γ ligands as a treatment for pituitary tumors and associated conditions, such as Cushing's syndrome
US20080206194A1 (en) Method for the treatment of breast cancer
US20040186166A1 (en) Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
US7812034B2 (en) Method of using protease inhibitors for the treatment of liposarcomas
US6586455B1 (en) Treatment of liposarcomas using a combination of thiazolidinediones and retinoid X receptor selective agonists
WO2008055317A1 (en) Compositions and methods for the treatment of prostate cancer
AU742981B2 (en) Treatment of disease states which result from neoplastic cell proliferation using PPAR-upsilon activators and compositions useful therefor
US20130116274A1 (en) Therapeutic combinations containing riluzole
WO2026074142A1 (en) Use of inhibitors of the n-acetylaspartate synthetase for the treatment of acute myeloid leukemias
AU2002245927B2 (en) Method for treatment of cancer and compositions for use therein
齋藤正浩 Troglitazone, a selective ligand for PPARγ, induces cell-cycle arrest in human oral SCC cells

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141211